Compositions and methods for improving skin appearance

Patent metadata

Field	Value
Publication number	US-2020345612-A1
Application number	US-202016877315-A
Country	US
Kind code	A1
Filing date	May 18, 2020
Priority date	Feb 9, 2015
Publication date	Nov 5, 2020
Grant date	—

Abstract

Injectable compositions and methods of treating skin can help improve hydration, elasticity and/or texture of the skin. The compositions can be based on crosslinked hyaluronic acid matrices made with low molecular weight hyaluronic acids.

First claim

What is claimed is:

1 . A method of improving at least one of texture, hydration, or elasticity of skin, the method comprising treating an area of skin by introducing into a skin region, in a single treatment session, multiple, spaced apart injections, of a composition comprising a hyaluronic acid (HA) gel comprising a crosslinked HA matrix made with more than 50% by weight, at least 70% by weight or at least 90% by weight of a low molecular weight HA material having a weight average molecular weight of between 400,000 Da and 800,000 Da, based on a total weight of the HA material;
wherein a HA concentration of the composition is 10.0 mg/g to 12 mg/g; and wherein the crosslinked HA matrix is crosslinked with a crosslinking agent selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane; wherein the injections are spaced apart by a distance of between 5 mm to 20 mm; and wherein the treated skin maintains at least one of an improved texture, hydration, or elasticity due to the treatment for at least 3 months.

2 . The method of claim 1 , wherein the injections are spaced apart by a distance of between 5 mm or 10 mm.

3 . The method of claim 1 , wherein the treated skin maintains the at least one of an improved texture, hydration, or elasticity due to the treatment for at least 4 months.

4 . The method of claim 3 , wherein the treated skin maintains the at least one of an improved texture, hydration, or elasticity due to the treatment for at least 6 months.

5 . The method of claim 4 , wherein the treated skin maintains the at least one of an improved texture, hydration, or elasticity due to the treatment for at least 9 months.

6 . The method of claim 5 , wherein the treated skin maintains the at least one of an improved texture, hydration, or elasticity due to the treatment for at least 12 months.

7 . The method of claim 1 , wherein the injections are introduced in an amount of 5 uL to 100 uL per injection.

8 . The method of claim 1 , wherein the treatment takes no longer than 45 minutes.

9 . The method of claim 1 , wherein the injections are delivered through a needle having a gauge of from 28 G to 33 G.

10 . The method of claim 1 , wherein the composition further comprises lidocaine in an amount of about 0.3% by weight of the composition.

11 . The method of claim 1 , wherein the composition further comprises mannitol in an amount of about 0.9% by weight of the composition.

12 . The method of claim 1 , wherein the composition further comprises ascorbic acid 2-glucoside in an amount of between about 0.3% to 0.6% by weight of the composition.

13 . The method of claim 1 , wherein the composition further comprises uncrosslinked HA in an amount of less than 10% by weight of the composition.

14 . The method of claim 1 , wherein about 90% by weight of the HA matrix is low molecular weight HA.

Assignees

• Allergan Ind Sas

Inventors

• Lebreton Pierre
• Guetta Olivier

Classifications

• A61K2800/91

  Injection · CPC title

• A61K8/735 Primary

  Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof · CPC title

• A61K8/42

  Amides · CPC title

• C08B37/0072

  Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates · CPC title

• A61K8/042

  Gels · CPC title